Clinical Implementation of a Polygenic Risk Score (PRS) for Breast Cancer

Breast Cancer Risk Clinical Trial

Official title:
Clinical Implementation of a Polygenic Risk Score (PRS) for Breast Cancer: Impact on Risk Estimates, Management Recommendations, Clinical Outcomes, and Patient Perception

Status Completed

Clinical Trial Summary

This study aims to assess how a polygenic risk score (PRS) reported with the results of multi-gene panel testing affects the breast cancer risk management recommendations healthcare providers make to their patients. The PRS is a score based on small genetic changes, clinical history, and family history. The PRS is used to estimate remaining lifetime risk of developing breast cancer for patients with no personal history of breast cancer and an overall negative result from MGPT.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03688204
Study type	Observational
Source	Ambry Genetics
Contact
Status	Completed
Phase
Start date	September 21, 2018
Completion date	November 11, 2020

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04082117` - Uptake of Genetic Counseling Among African American Women	N/A
Completed	`NCT05082740` - FH-Risk 2.0: Updating Breast Cancer Risk Estimates
Not yet recruiting	`NCT05848856` - The RISC Registry--Risk Informed Screening Registry
Completed	`NCT00839696` - Total Xenoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Rlisk
Recruiting	`NCT04248257` - Peer Support For Young Adult Women With High Breast Cancer Risk	N/A
Enrolling by invitation	`NCT04265547` - Family-Based Intervention Study of the Effects of Environmental Exposures on Breast Tissue Composition	N/A
Completed	`NCT01511276` - The Effects of Equivalent Weight Loss With or Without Exercise Training on Breast Cancer Risk (SHAPE-2)	N/A
Completed	`NCT00555386` - Soy, Selenium and Breast Cancer Risk	N/A